S&P Futures
6,002.25 -1.50 (-0.02%) Dow Futures
43,896.00 -14.00 (-0.03%) Nasdaq Futures
21,196.75 -28.00 (-0.13%) Russell 2000 Futures
2,395.00 -0.70 (-0.03%) Crude Oil
71.08 -1.28 (-1.77%) Gold
2,692.20 -13.60 (-0.50%)
Idorsia Ltd (IDRSF)
| Previous Close | 0.0000 |
| Open | 2.2500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.2500 - 2.2500 |
| 52 Week Range | 1.0900 - 2.8800 |
| Volume | |
| Avg. Volume | 359 |
| Market Cap | 197.584M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | 5.74 |
| EPS (TTM) | 0.1900 |
| Earnings Date | Oct 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireIdorsia announces financial results for the first nine months of 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. Highlights Net revenue 9M 2024 at CHF 53 million.US GAAP operating loss 9M 2024 of CHF 154 million and Non-GAAP operating loss of CHF 248 million.Improved Guidance for 2024, driven by diligent cost control.QUVIVIQ™ (daridorexant) total net sales of CHF 39 million in 9M 2024.Commercial partnership for QUVIVIQ with Men
- GlobeNewswire
New data on aprocitentan to be presented at the ASN Kidney Week 2024
Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of Nephrology (ASN) Kidney Week 2024, taking place in San Diego, CA, October 23–27, 2024. The following oral and poster presentations will be held, highlighting the promising results of using aprocitentan for patients with hypertension not adequately controlled with other medications, with positive eff
